Compare First Citizens BancShares Inc (FCNCA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs TG Therapeutics Inc — how do they compare? First Citizens BancShares Inc trades at $2,278.08 (market cap $25.04B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: First Citizens BancShares Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FCNCA | TGTX | |
|---|---|---|
Market Cap | $25.04B | $7.64B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $59.06 |
52-Week Low | $1.64K | $26.94 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,276, up 1.91% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by recent earnings beats. Recent news highlights business expansion, including new financing groups and real estate acquisitions.
Outlook is positive with analyst consensus price target of $2,310, though most analysts rate it Hold. Key risks include elevated uninsured deposits and net interest margin pressure. Earnings growth and strategic initiatives provide upside potential, but investor caution is warranted near current levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
